Physicians' Academy for Cardiovascular Education
Member

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
Implementation of PCSK9 inhibition in clinical practice before the outcome data

CSI Rome Terje Pedersen defended the 'contra'-argument in a discussion on the use of PCSK9 inhibitors in current clinical practice. He explains to Lotte Koopal and Gijs Berkelmans that while being involved in clinical studies of a PCSK9 antibody, he is still comfortable in the contra-position.

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
A minority of FH patients is identified and labeled as such, which impacts treatment

CSI Rome Kausik Ray was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint discuss the consequences of underdetection with him, and how this may be improved.

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)
Possible approaches in precision medicine for secundary CV prevention

CSI Rome Nicole Jaspers en Gijs Berkelmans discuss the role of precision medicine in secondary prevention with Dr. Noel Bairey Merz, as well as which approaches and types of data can be considered to assess risk.

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).
Lower than the currently recommended ApoB targets may be more useful for clinical decision-making.

CSI Rome Analysis of ApoB levels in the NHANES population revealed that guideline recommended ApoB targets have limited value in clinicial practice. Lotte Koopal and Gijs Berkelmans discuss these insights with Dr. Seth Shay Martin and Dr. Allan Sniderman.

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)
Bisphosphonates may impact calcification of the arterial intima media.

CSI Rome Guido Kranenberg studied the potential impact of bisphosphonate on calcification of the arterial intima media. He shares the findings of a systematic review and meta-analysis with Nicole Jaspers and they discuss which other studies might shed light on this relationship.

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

CSI Rome Robert Horne is a Professor of Behavioural Medicine at University College London, United Kingdom who studies treatment non-adherence. Monique van Kleef discusses with him why this is a particular problem in hypertension, and how this may be improved.

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
CV benefit that can be achieved with the new glucose-lowering SGLT2-inhibitor empagliflozin in diabetes

CSI Rome Manon Slob and Shahnam Sharif extensively discuss the results of the EMPA-REG OUTCOME study, the first outcomes trial with an SGLT2 inhibitor, with Prof. Silvio Inzucchi, including what the results may mean for the management of diabetes.

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)
FIrst results of the CALM-FIM study, a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.

CSI ROME Nicolette van der Sande and Monique van Kleef question Wilko Spiering about the interim results of the CALM-FIM study. This was a first-in-man study with a new device (MobiusHD) for patients with treatment resistant hypertension.

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
Residual CV risk consists of cholesterol and inflammatory residual risk. How can these aspects be addressed to lower CV risk?

CSI ROME Nicole Jaspers and Manon Slob interview Prof. Paul Ridker about the concept of residual risk and how the different forms may be targeted with novel therapeutic strategies to further lower CV risk.

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
Two professors disagree on whether the results of the SPRINT trial on blood pressure lowering should influence new guidelines.

CSI ROME Nicolette van der Sande and Monique van Kleef critically discuss the SPRINT trial results with William Cushman and Sverre Kjeldsen. The professors disagree on whether these results should influence new guidelines.

10' education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)